Ivermectin: From Parasites to Autism — How Drug Advocates Shifted to a New Target After the Pandemic

Ivermectin — an antiparasitic drug developed in the 1970s (S001), awarded the Nobel Prize for its contribution to combating tropical diseases. Its primary use — treatment of onchocerciasis and strongyloidiasis.

During the COVID-19 pandemic, the drug became the object of mass belief in its antiviral properties, despite the absence of quality clinical data. After the pandemic subsided, communities of ivermectin supporters did not disappear — they redirected their focus to other conditions, including autism, chronic fatigue, and autoimmune diseases. More details in the section Logic and Probability.

🧩 Defining the Boundaries of the Phenomenon: What Exactly Migrated

Migration of a pseudoscientific narrative is a process whereby a group of supporters of an unproven treatment method transfers their activity from one disease to another, while preserving the rhetoric, argument structure, and social networks of information dissemination.

What migrated with ivermectin:

Online communities and Telegram channels, willing physicians, self-treatment protocols, commercial structures selling the drug without prescription.

What remained unchanged:

Rhetoric ("official medicine is hiding the truth"), structure of "evidence" (in vitro studies, cherry-picking data), appeals to the authority of individual doctors.

⚠️ Why Autism Became the New Target: Anatomy of a Vulnerable Audience

Parents of children with autism spectrum disorders (ASD) represent a particularly vulnerable group for pseudoscientific narratives. Autism is a condition with unclear etiology, absence of universal treatment, and high variability of manifestations.

Official medicine offers behavioral therapy and developmental support, but not a "cure." This creates space for alternative proposals, especially when they are packaged in medical terminology and supported by anecdotal evidence of "improvements."

Vulnerability is amplified by the availability heuristic — parents more easily remember stories about "improvements" on social media than statistics showing absence of effect in studies.

🔁 Narrative Structure: What Remained Unchanged in the Transition from COVID to Autism

The rhetoric of ivermectin supporters in autism is practically identical to that used during the pandemic. The structure of "evidence" is also preserved: references to in vitro studies, incorrect interpretation of mechanisms of action, cherry-picking data.

This is not coincidental — confirmation bias and groupthink create conditions under which one successful narrative structure is easily adapted to a new target.

For objective analysis, we must examine the most compelling arguments from proponents of ivermectin use in autism in their strongest formulation. This avoids straw man fallacies and helps us understand why these arguments resonate with parents. Learn more in the Epistemology section.

🔬 Argument 1: Anti-inflammatory Properties and Neuroinflammation in Autism

Proponents argue that ivermectin has anti-inflammatory properties, and some research points to a role of neuroinflammation in autism pathogenesis. The logic: if the drug reduces inflammation, and inflammation is linked to autism, then the drug may improve symptoms.

This argument draws on real research into ivermectin's anti-inflammatory effects (S001) in vitro and the hypothesis about immune dysregulation in ASD. However, this involves ignoring the base rate: the presence of inflammation in autism doesn't mean an anti-inflammatory drug will solve the problem.

🧬 Argument 2: GABA Receptor Modulation and Behavioral Symptoms

Ivermectin acts on chloride channels linked to GABA receptors in parasites. Proponents extrapolate this to the human nervous system, suggesting the drug might influence the excitation-inhibition balance in the brain, which is disrupted in autism.

This argument uses the drug's actual mechanism of action but ignores a critical distinction: parasite and mammalian receptors have different structures and sensitivities. Extrapolating from parasite to human brain is a logical leap, not a scientific conclusion.

📊 Argument 3: Anecdotal Evidence of Improvements from Parents

Numerous parents in online communities report improvements in speech, social interaction, and reduced stereotypical behavior in their children after starting ivermectin. These testimonials are often detailed, emotional, and accompanied by video recordings.

For parents desperate to find help, such stories become powerful motivators to try the drug. The availability heuristic is at work here: vivid, emotional stories seem more convincing than statistics. But anecdotes don't control for placebo effect, natural development, concurrent interventions, and selection bias.

🧪 Argument 4: Drug Safety and the "Do No Harm" Principle

Ivermectin has been used for decades to treat parasitic infections and has an established safety profile with proper dosing. Proponents argue that even without proven efficacy in autism, the low risk of side effects justifies attempting its use.

1. The drug is safe for approved indications and standard doses
2. Long-term use at non-standard doses is an entirely different scenario
3. Absence of harm ≠ presence of benefit
4. The "do no harm" principle requires balance: risk vs. proven efficacy

⚙️ Argument 5: Antiparasitic Hypothesis and Gut Microbiome

Some proponents suggest autism may be linked to parasitic infections or gut microbiome imbalance, and ivermectin, by acting on parasites and potentially on microbiota, could improve symptoms through the gut-brain axis.

This argument leverages real scientific interest in the microbiome's role in autism (S005), but makes unfounded leaps: from "the microbiome may be involved" to "ivermectin will solve the problem." This is a classic false dichotomy—assuming one cause explains everything.

🧾 Argument 6: Distrust of the Pharmaceutical Industry and Conflicts of Interest

Proponents point out that ivermectin is a cheap generic drug, and pharmaceutical companies have no interest in researching it for new indications because it won't generate profit. They claim the absence of large clinical trials is explained by economic reasons, not lack of potential.

This argument resonates with general distrust of "Big Pharma" and creates a narrative about a "hidden cure." However, it ignores: government grants fund research regardless of profitability; absence of evidence after decades of use is itself evidence; academic groups can research cheap drugs without commercial interest.

🔁 Argument 7: Parental Right to Choose Treatment and Informed Consent

The final argument appeals to parental autonomy: if they're informed about risks and potential benefits, they have the right to try ivermectin for their child, especially when conventional medicine offers no "cure."

This argument invokes the ethical principle of patient autonomy but contains a critical flaw: informed consent requires objective information, not distorted pseudoscientific rhetoric. When parents receive filtered information from echo chambers, this isn't informed consent—it's manipulation disguised as choice.

To assess the validity of using ivermectin for autism, we must turn to evidence-based medicine methodology. Systematic reviews and meta-analyses represent the highest level of evidence, as they synthesize data from multiple studies while controlling for systematic errors. Learn more in the Scientific Method section.

📊 Systematic Review Methodology: The Gold Standard for Efficacy Assessment

A systematic review is a study that uses explicit, reproducible methods to identify, select, and critically evaluate all relevant research on a specific question (S003). Meta-analysis adds statistical pooling of results to obtain a summary effect estimate.

The methodology includes searching multiple databases (Embase, MEDLINE, Cochrane Central Register of Controlled Trials), assessing risk of bias, and analyzing heterogeneity of results (S003).

🧪 Absence of Ivermectin Studies for Autism in Major Databases

Searches of clinical trial databases reveal not a single completed randomized controlled trial (RCT) of ivermectin for autism spectrum disorders. This is a critically important fact: the absence of studies does not mean "unexplored possibility," but rather the absence of preliminary data that would justify conducting such studies.

In evidence-based medicine, progression to human clinical trials requires compelling evidence of mechanism of action and efficacy in preclinical models. These do not exist.

🔎 Extrapolating Anti-Inflammatory Effects Data: The Translation Problem

Studies of ivermectin's anti-inflammatory properties have been conducted predominantly in vitro (test tube) or in animal models unrelated to autism. Extrapolating such data to humans and to a specific condition requires multiple intermediate steps.

1. Evidence of achieving therapeutic concentrations in the brain
2. Absence of toxicity with long-term use
3. Relevance of mechanism to autism pathogenesis

None of these steps have been completed for ivermectin and autism.

📉 Lessons from Systematic Reviews of Other Conditions: Patterns of Low-Quality Evidence

Systematic reviews of ivermectin use for COVID-19 revealed critical problems: high risk of bias in studies, small sample sizes, lack of blinding, selective publication of results, and even cases of data fabrication. These patterns are characteristic of situations where enthusiasm outpaces evidence.

Similar problems are observed in the literature on alternative autism treatments: an abundance of case reports with an absence of controlled studies. This is related to confirmation bias—researchers and clinicians see what they expect to see.

🧾 Heterogeneity of Results and the Plateau Effect Problem in Research

Systematic reviews often encounter the problem of heterogeneity—differences in results between studies that make it difficult to obtain a unified effect estimate. A study on colon adenomas showed that after a certain threshold of diagnostic quality, further improvement does not lead to risk reduction, demonstrating a "plateau effect" (S005).

⚠️ Systematic Errors in Data Interpretation by Ivermectin Proponents

Analysis of ivermectin proponents' rhetoric reveals classic systematic errors: cherry-picking (selective citation of studies supporting the hypothesis), ignoring negative results, misinterpreting statistical significance, conflating correlation and causation.

These errors are not random—they systematically distort perception of evidence in favor of the desired conclusion. This is related to ignoring base rates: proponents focus on rare positive cases while ignoring the overall statistics of no effect.

Assessing biological plausibility is a critical stage in analyzing any therapeutic claim. Even with positive clinical data (which doesn't exist for ivermectin and autism), it's necessary to understand whether a plausible mechanism of action exists. More details in the Cognitive Biases section.

🧬 Ivermectin Pharmacokinetics: The Blood-Brain Barrier Penetration Problem

Ivermectin is a lipophilic molecule that poorly penetrates the blood-brain barrier (BBB) in healthy mammals (S001). This is an evolutionary protection: the drug should act on parasites in peripheral tissues without affecting the host's central nervous system.

Ivermectin concentrations in the brain at standard doses are tens of times lower than in blood plasma. To achieve concentrations that show in vitro effects on neuronal receptors would require toxic doses.

🔬 Differences Between Parasite and Mammalian GABA Receptors

Ivermectin binds to glutamate-gated chloride channels in invertebrates, causing parasite paralysis. Mammals lack such channels.

Mammalian GABA receptors have different structure and pharmacology. While at very high concentrations ivermectin can affect mammalian GABA receptors, these concentrations are not achieved at therapeutic doses and are accompanied by toxicity. Extrapolating the mechanism of action from parasites to humans is a fundamental biological error.

1. Parasites: glutamate-gated chloride channels → paralysis at low ivermectin doses
2. Mammals: GABA receptors with different architecture → toxic doses required for effect
3. Conclusion: the mechanism doesn't transfer between species

🧪 Anti-inflammatory Effects: Doses, Timing, and Relevance

The anti-inflammatory effects of ivermectin observed in vitro require concentrations 10-100 times higher than those achievable in blood plasma at standard doses (S001). Moreover, these effects were studied in the context of acute inflammation, not the chronic neuroinflammatory processes hypothesized in autism.

The timeframes also don't match: autism is a developmental disorder manifesting in early childhood, not an acute inflammatory disease. Applying a drug developed for acute inflammation to a chronic neurodevelopmental disorder is a categorical error.

🔁 The Causality Problem: Correlation Between Neuroinflammation and Autism Doesn't Mean a Therapeutic Target

Even if neuroinflammation is present in autism (which remains a subject of debate), this doesn't mean it causes symptoms or that suppressing it will improve the condition. Inflammation may be a secondary process, compensatory mechanism, or epiphenomenon.

Medical history is full of examples where suppressing biological processes that correlate with disease didn't lead to clinical improvement or even worsened the condition. This is a classic error of ignoring base rates in biological thinking: the presence of a marker doesn't guarantee its role in pathogenesis.

⚙️ Absence of Preclinical Models: A Missing Step in Translational Medicine

Translational medicine requires a sequence: mechanism → cellular models → animal models → clinical trials (S006). For ivermectin in autism, convincing data from ASD animal models is absent.

No study has shown that ivermectin improves autism-related behavioral phenotypes in genetically modified mice or other models. This missing step is critical: it should have preceded any attempts at use in children.

Translational Gap

The absence of preclinical data means the mechanistic hypothesis was never tested in biological systems close to the human brain.

Risk-Benefit Without a Mechanism

Without a plausible mechanism, any side effects become unjustifiable, as there's no theoretical basis for expecting benefit.

Scientific literature shows not just an absence of evidence for ivermectin's effectiveness in autism, but systematic fractures in the methodology of alternative treatment research. More details in the Psychology of Belief section.

📊 Heterogeneity in Defining "Improvement" in Autism

The main problem: there's no consensus on what constitutes "improvement." Parents record subjective observations that don't align with standardized assessments.

Research on cognitive function in other conditions confirms the critical importance of validated instruments (S001). Without them, anecdotal evidence remains just stories, not proof.

When there's no unified definition of success, everyone sees what they want to see.

🔎 Publication Bias in Alternative Treatment Literature

Positive results get published more often than negative ones (S003). In the field of alternative autism treatments, this is amplified: small studies with positive results make it into low-impact journals, while negative ones stay in file drawers.

The result: systematic analysis of available literature creates an illusion of effectiveness, even though the real picture is the opposite.

⚠️ Conflict Between Biology and Anecdote

A fundamental divide: there's no biologically plausible mechanism for ivermectin's action in autism, yet numerous parental testimonials report improvements.

This conflict resolves through availability heuristic and confirmation bias: placebo effect, natural symptom variability, regression to the mean, cognitive distortions in perceiving change. Systematic studies of other autism interventions show: subjective improvements often aren't confirmed by objective assessment.

Placebo Effect

Expectation of improvement activates neurobiological mechanisms that genuinely reduce symptom perception—without changing the symptoms themselves.

Regression to the Mean

If a parent starts treatment at peak symptom severity, natural fluctuation will look like improvement from the drug.

Cognitive Distortion

The brain seeks confirmation of expectations and reinterprets neutral events as positive ones.

🧾 Safety: Short-term vs Long-term

Ivermectin's safety profile is established for short-term use in parasitic infections. Data on long-term safety with chronic use, especially in children with developing nervous systems, is limited.

A systematic review on ketamine showed: even well-studied drugs can have unexpected long-term effects with off-label use (S003). Extrapolating short-term safety to long-term use is a methodological error frequently made in alternative medicine communities.

Absence of evidence of harm over 3 months doesn't equal proof of safety over 3 years.

The ivermectin-for-autism myth persists not on facts, but on the architecture of human thinking. Understanding these mechanisms isn't an excuse for believers—it's a map of vulnerabilities that any pseudomedical narrative exploits. More details in the Electromagnetism section.

🧩 Availability Heuristic: Vivid Stories vs. Statistics

The availability heuristic occurs when the brain overestimates the probability of an event if vivid examples are easily recalled. A video of a mother describing an ivermectin "miracle" is psychologically more powerful than a table showing zero effect in an RCT.

One emotional narrative with a face, name, and details activates imagination. A hundred anonymous patients in statistics—doesn't.

The brain doesn't calculate probabilities. It searches for patterns in memory. If a pattern is vivid—it seems frequent, even if it's rare.

🔄 Confirmation Bias and Echo Chambers: The Filter That Amplifies the Signal

Confirmation bias—the brain seeks information that confirms already-formed beliefs and ignores contradictory data. In closed groups of ivermectin supporters, this mechanism operates at full capacity.

Each new post about "success" reinforces confidence. Critical articles are perceived as "pharmaceutical company censorship." Contradiction doesn't weaken belief—it strengthens it.

1. Person believes in ivermectin
2. Sees post confirming belief → joy, shares it
3. Sees criticism → perceives as attack → believes even more
4. Environment (group) reinforces conviction → social pressure

⚖️ Base Rate Neglect: Why 1 Improvement Seems Like Proof

Base rate is the background probability of an event in a population. With autism, spontaneous improvements occur naturally: brain development, adaptation, placebo effect, coincidence with other interventions.

If 5% of children with autism improve on their own, and a parent gives ivermectin during this period—they see causation, though it's correlation. Base rate neglect makes coincidence indistinguishable from effect.

🎭 Social Proof and Groupthink

People believe what other people believe, especially if those people are similar to them. Groupthink turns doubt into betrayal of the group.

When hundreds of parents say "ivermectin helped my child," it creates social pressure. Criticism is perceived not as scientific argument, but as an attack on the group to which a person belongs.

Social Proof

If everyone believes—it must be true. If I don't believe—I'm alone against everyone, which is psychologically painful.

Group Identity

"We're those who don't trust mainstream medicine." Rejecting ivermectin = betraying the group, losing identity.

Authority Hierarchy Within the Group

Opinion leaders (often without medical training) become "experts." Their word weighs more than RCTs.

🚪 False Dichotomy: "Mainstream Medicine" vs. "Alternative"

False dichotomy—dividing the world into two camps: "them" (pharmaceutical companies, scientists, enemies) and "us" (parents, truth fighters). Reality is more complex, but black-and-white thinking is simpler.

If ivermectin doesn't work for autism—that doesn't mean mainstream medicine is right about everything. But the narrative doesn't allow nuance: you're either with us or you're the enemy.

The myth survives not because it's true. It survives because it's socially useful: it provides answers, identity, an enemy, and hope. Facts are an obstacle.

Destroying such a myth with facts is impossible. You need to offer an alternative: a different identity, different hope, a different explanation of reality that doesn't require denying science.